Will Pfizer (PFE) Make a Play for Struggling GlaxoSmithKline (GSK)?
Celgene (CELG) Picks Up San Francisco Biotech Quanticel in $485 Million Deal
In Fight Against Alzheimer's, $100 Million Genentech (RHHBY) Trial in Colombia May Be Ground Zero
Procter & Gamble (PG) to Axe Up to 6,000 Office Jobs Worldwide Amid Criticism It Might Not Be Enough
Sobi Waves For Sale Sign at Big Pharmas Like Pfizer (PFE), Biogen (BIIB)
Prior to FDA Vote, Advisory Committee Cites Study Bias Concerns Over Amgen (AMGN) Cancer Vaccine
In Testy Letter to Teva (TEVA)'s CEO, Mylan (MYL) Rejects Its $40B Bid, Questions Credibility
Celladon (CLDN) Will Lay Off Workers, Loses 80% of Value As Heart Failure Drug Flunks Phase IIb Trial
Seattle Genetics (SGEN) to Hire 100 Employees in Anticipation of Company Growth
Celgene (CELG) Slaps Down $450 Million Upfront for AstraZeneca PLC (AZN)'s Prized Immunotherapy Blood Cancer Drug
EXCLUSIVE: Jounce CEO Says Funding Aims for Trials Next Year, Will Hire 10
Innate Pharma (IPH.PA ) Strikes Cancer Pact Worth $1.275 Billion With Pharma Giant AstraZeneca PLC (AZN)
Small Biotech Clovis Oncology (CLVS)'s Breakthrough Drugs May Catch the Eye of Pfizer (PFE), Roche (RHHBY)
Aerie (AERI) Freefalls Aftermarket as Rhopressa Fails Phase III Study
As Mylan (MYL), Perrigo (PRGO) and Teva (TEVA) Maneuver For Acquisitions, 30,000 Jobs Hang in the Balance
Merck & Co. (MRK) Poised To Enter Oral HCV Market Dominated by Gilead (GILD) and AbbVie (ABBV)
Amgen (AMGN) Boasts 51% Rise in Profit, Abandons Phase II Brodalumb Study, but Pushes Biosimilars
Why Ariad (ARIA) Could Be Worth $3 Billion to a Big Drugmaker
See All News >
Seattle Genetics (SGEN) to Hire 100 Employees in Anticipation of Company Growth
Celgene (CELG) Slaps Down $450 Million Upfront for AstraZeneca PLC (AZN)'s Prized Immunotherapy Blood Cancer Drug
EXCLUSIVE: Jounce CEO Says Funding Aims for Trials Next Year, Will Hire 10
Innate Pharma (IPH.PA ) Strikes Cancer Pact Worth $1.275 Billion With Pharma Giant AstraZeneca PLC (AZN)
Small Biotech Clovis Oncology (CLVS)'s Breakthrough Drugs May Catch the Eye of Pfizer (PFE), Roche (RHHBY)
The Ten Most Hated Companies In Healthcare
Aerie (AERI) Freefalls Aftermarket as Rhopressa Fails Phase III Study
As Mylan (MYL), Perrigo (PRGO) and Teva (TEVA) Maneuver For Acquisitions, 30,000 Jobs Hang in the Balance
Merck & Co. (MRK) Poised To Enter Oral HCV Market Dominated by Gilead (GILD) and AbbVie (ABBV)
Amgen (AMGN) Boasts 51% Rise in Profit, Abandons Phase II Brodalumb Study, but Pushes Biosimilars
Why Ariad (ARIA) Could Be Worth $3 Billion to a Big Drugmaker
Texas Psychiatrists Accused of Accepting Bribes from AstraZeneca PLC (AZN) to Manipulate State Formulary
Could Google (GOOG) Be a Buyer for Former Merck & Co. (MRK) HQ?
Jounce Infused With $56 Million to Develop Cancer Immunotherapy Programs
Gilead (GILD) Offers Free Drugs in Georgia in Hep C Eradication Experiment
How Abbott (ABT) is Reaping Rewards From Teva (TEVA)'s Bid for Mylan (MYL)
Novartis AG (NVS) Hunts for Bolt-On Acquisitions Worth $2 Billion to $5 Billion
Rumors Swirl Pfizer (PFE) Will Bid for AstraZeneca PLC (AZN) Again
See All News >
//-->